Bruce E Johnson
Overview
Explore the profile of Bruce E Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
262
Citations
28456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barrichello A, Elkrief A, Ricciuti B, Ganta T, Marron T, Wang X, et al.
Clin Lung Cancer
. 2025 Feb;
PMID: 40021433
Background: Non-small cell lung cancer (NSCLC) patients aged ≥80 years [y] are underrepresented in clinical trials. We evaluated whether age correlates with a distinct immunophenotype or impacts outcomes to first-line...
2.
Gandhi M, Elkrief A, Moore C, Ricciuti B, Alessi J, Richards A, et al.
J Thorac Oncol
. 2025 Jan;
PMID: 39864548
Introduction: Mutations in STK11, KEAP1, and SMARCA4 predispose to inferior immune checkpoint inhibitor (ICI) efficacy in NSCLC, particularly among KRAS-mutant cases. Nevertheless, the frequency, clinicopathologic features, and clinical impact of...
3.
Perez K, Kulke M, Zheng H, Allen J, Clark J, Enzinger A, et al.
Oncologist
. 2025 Jan;
30(1.
PMID: 39834129
Objectives: Well-differentiated neuroendocrine tumors (NET) are highly vascular tumors characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of ramucirumab, a monoclonal antibody that...
4.
Dagogo-Jack I, Cooper A, Johnson B, Gainor J, Lin J, Sequist L, et al.
Lung Cancer
. 2024 Nov;
199:108003.
PMID: 39615410
Introduction: Anaplastic lymphoma kinase rearranged (ALK + ) lung cancers often develop ALK-independent resistance mechanisms that reactivate the mitogen-activated protein kinase pathway signaling pathway. We therefore evaluated alectinib combined with...
5.
Klughammer J, Abravanel D, Segerstolpe A, Blosser T, Goltsev Y, Cui Y, et al.
Nat Med
. 2024 Oct;
30(11):3236-3249.
PMID: 39478111
Although metastatic disease is the leading cause of cancer-related deaths, its tumor microenvironment remains poorly characterized due to technical and biospecimen limitations. In this study, we assembled a multi-modal spatial...
6.
Fox A, Osarogiagbon R, Farjah F, Jett J, Johnson B, Rivera M, et al.
Cancer
. 2024 Sep;
130(24):4188-4199.
PMID: 39347617
Comprehensive biomarker testing is a crucial requirement for the optimal treatment of advanced-stage non-small cell lung cancer (NSCLC), with emerging relevance in the adjuvant treatment setting. To advance its goal...
7.
Roy-Chowdhuri S, Mani H, Fox A, Tsao A, Sholl L, Farjah F, et al.
Cancer
. 2024 Sep;
130(24):4200-4212.
PMID: 39347608
Comprehensive biomarker testing for patients with non-small cell lung cancer is critical for selecting appropriate targeted therapy or immunotherapy. Ensuring timely ordering, processing, and reporting is key to optimizing patient...
8.
Forrest S, Gupta H, Ward A, Li Y, Doan D, Al-Ibraheemi A, et al.
Nat Commun
. 2024 Aug;
15(1):7218.
PMID: 39174503
No abstract available.
9.
Meyer M, Hirsch F, Bunn P, Ujhazy P, Fredrickson D, Berg C, et al.
Oncologist
. 2024 Jul;
29(12):e1634-e1645.
PMID: 39002167
Lung cancer, the leading cause of cancer-related deaths globally, remains a pressing health issue despite significant medical advances. The New York Lung Cancer Foundation brought together experts from academia, the...
10.
Forrest S, Gupta H, Ward A, Li Y, Doan D, Al-Ibraheemi A, et al.
Nat Commun
. 2024 Jul;
15(1):5837.
PMID: 38992034
To inform clinical trial design and real-world precision pediatric oncology practice, we classified diagnoses, assessed the landscape of mutations, and identified genomic variants matching trials in a large unselected institutional...